1. Editorial
The
introduction of Magnetically Controlled Growing Rods (MCGRs) was widely
regarded as a paradigm shift in the management of Early Onset Scoliosis (EOS).
By replacing repeated surgical lengthenings with non-invasive outpatient
distractions, the technology promised to reduce the cumulative burden of
surgery while preserving spinal and thoracic growth1. More than a decade later, however, it is legitimate to ask
whether these expectations have truly been fulfilled. While MCGRs undoubtedly
represented an elegant engineering solution, growing clinical evidence suggests
that they have failed to overcome many of the fundamental limitations of
growth-friendly surgery and, in some respects, have introduced entirely new
challenges2-9.
The
greatest strength of MCGRs-the elimination of repeated surgical
distractions-rapidly became their principal marketing message. Unfortunately,
this message has often overshadowed a less reassuring reality. Eliminating
planned procedures has not eliminated complications. Instead, scheduled
operations have largely been replaced by unplanned revisions resulting from
implant failure, loss of distraction, anchor pull-out, rod fracture or deep
infection2-5. Contemporary systematic
reviews report overall complication rates approaching 40% to 45%, while
unplanned revision surgery remains necessary in approximately one-quarter to
one-third of patients2-4.
Consequently, the overall surgical burden for many patients has been reduced
less than initially anticipated, raising the question of whether the technology
has genuinely altered the natural history of growth-friendly treatment or
merely shifted the timing and indication for surgery.
Perhaps
the most disappointing aspect of the MCGR experience is the durability of the
implant itself. Any technology designed for children undergoing years of spinal
growth should be expected to function reliably over prolonged periods. Yet
retrieval analyses consistently demonstrate internal locking-pin fractures,
actuator wear, corrosion, O-ring failure and complete loss of distraction
capability8,9. These findings are
particularly concerning because mechanical failure is frequently occult: the
external remote controller may indicate successful distraction while the
implant no longer elongates8,9. Such
silent failures undermine one of the principal advantages claimed for the
technology and expose a fundamental weakness in relying on external distraction
measurements without independent radiographic verification.
Equally
concerning is the biological response generated by these implants. Metallosis
was initially considered an isolated retrieval finding but has progressively
emerged as a reproducible phenomenon across multiple clinical and retrieval series6,8,9. Titanium wear debris, local inflammatory
reactions, pigment deposition and elevated serum titanium concentrations are
now well documented6,8. Although
definitive evidence of systemic toxicity remains lacking, absence of evidence
should not be interpreted as evidence of safety. Children with EOS represent
one of the youngest populations exposed to long-term spinal instrumentation and
the biological consequences of chronic metallic debris over several decades
remain unknown. This uncertainty alone should encourage greater caution than
has sometimes characterized clinical enthusiasm.
Another
important lesson from long-term follow-up is that spinal growth cannot simply
be “programmed” through periodic magnetic distractions. Progressive stiffness,
spontaneous autofusion, soft-tissue contracture, implant wear and increasing
construct rigidity contribute to the well-recognized phenomenon of diminishing
distraction gains5-7. Consequently,
the theoretical advantage of repeated non-invasive lengthening gradually erodes
over time. In practice, the discrepancy between intended distraction and
achieved spinal growth may become substantial, suggesting that mechanical
elongation of the rod is not synonymous with biological growth of the spine.
Equally
problematic is the quality of the evidence supporting widespread MCGR adoption.
Despite more than a decade of clinical use, the literature remains dominated by
retrospective case series, heterogeneous patient populations, limited follow-up
and relatively small cohorts2-7.
High-level comparative evidence is remarkably scarce, while randomized studies
are entirely absent. Meta-analyses consistently conclude that MCGRs provide
deformity correction and spinal growth comparable to traditional growing rods,
but without convincing evidence of superior long-term clinical outcomes or
lower complication rates3,7.
Nevertheless, MCGRs were rapidly embraced by many centers worldwide before
robust long-term evidence became available. This sequence-enthusiastic adoption
preceding definitive evaluation-is increasingly familiar in surgical innovation
and should prompt reflection within the spine community.
The
regulatory history of the MAGEC system further reinforces this concern. Safety
alerts issued by regulatory agencies, field safety notices, reports of end-cap
separation, actuator failure, corrosion and metallosis have highlighted
shortcomings that only became fully apparent after widespread clinical
implementation8,9. These events
expose an uncomfortable reality: post-market surveillance, rather than
pre-market evidence, ultimately identified many of the technology's most
important limitations. Such experience should encourage greater scrutiny before
new implant technologies become widely adopted, particularly in vulnerable
pediatric populations.
Economic
arguments have also become less persuasive with time. Early analyses emphasized
the avoidance of repeated surgical lengthenings and predicted substantial
long-term savings5. Those
calculations, however, assumed durable implant performance. Once revision
surgery, implant exchange, prolonged follow-up, repeated imaging and management
of complications are incorporated, the economic advantage becomes considerably
less certain5,7. Cost-effectiveness,
therefore, cannot be evaluated independently of implant longevity.
None
of these criticisms imply that MCGRs should be abandoned. For appropriately
selected patients, they remain a valuable option capable of reducing repeated
anesthetic exposure and improving family convenience1,5. However, they should no longer be portrayed
as a definitive solution to the challenges of EOS. Rather, they represent an
important technological advance whose limitations have become as informative as
its successes.
Perhaps the most enduring legacy of MCGRs will not be the device itself but the lesson it has taught. Innovation alone is insufficient. In pediatric spinal deformity surgery, technological elegance cannot substitute for mechanical reliability, biological safety and robust long-term evidence. The history of MCGRs reminds us that reducing the invasiveness of treatment is meaningful only if durability, safety and clinical outcomes improve in parallel. Future generations of growth-friendly implants should be judged not by the novelty of their engineering but by their capacity to deliver sustained benefits over the many years that children with EOS require treatment.
2. References